Citius Oncology, Inc. (NASDAQ:CTOR) Short Interest Update

Citius Oncology, Inc. (NASDAQ:CTOR) was the target of a significant decrease in short interest in February. As of February 13th, there was short interest totaling 913,552 shares, a decrease of 24.7% from the January 29th total of 1,213,142 shares. Approximately 1.1% of the shares of the company are short sold. Based on an average daily volume of 183,334 shares, the days-to-cover ratio is currently 5.0 days. Based on an average daily volume of 183,334 shares, the days-to-cover ratio is currently 5.0 days. Approximately 1.1% of the shares of the company are short sold.

Citius Oncology Price Performance

Citius Oncology stock traded down $0.04 during mid-day trading on Monday, hitting $1.08. 97,598 shares of the company were exchanged, compared to its average volume of 196,670. The company has a market capitalization of $95.34 million, a PE ratio of -3.48 and a beta of 3.02. The business has a fifty day moving average of $1.12 and a 200 day moving average of $1.44. Citius Oncology has a 1-year low of $0.55 and a 1-year high of $6.19. The company has a quick ratio of 0.32, a current ratio of 0.83 and a debt-to-equity ratio of 0.07.

Citius Oncology (NASDAQ:CTOR) last posted its earnings results on Friday, February 13th. The company reported ($0.06) earnings per share for the quarter, hitting the consensus estimate of ($0.06). The firm had revenue of $3.94 million during the quarter, compared to the consensus estimate of $4.37 million.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Citius Oncology in a report on Monday, December 22nd. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $6.00.

Institutional Investors Weigh In On Citius Oncology

A number of hedge funds and other institutional investors have recently bought and sold shares of CTOR. IFP Advisors Inc boosted its stake in shares of Citius Oncology by 163.2% in the 4th quarter. IFP Advisors Inc now owns 87,424 shares of the company’s stock valued at $87,000 after purchasing an additional 54,209 shares during the last quarter. Arkadios Wealth Advisors acquired a new position in Citius Oncology in the second quarter valued at approximately $51,000. OMERS ADMINISTRATION Corp bought a new position in Citius Oncology in the fourth quarter valued at approximately $104,000. Geode Capital Management LLC lifted its stake in shares of Citius Oncology by 31.6% in the 4th quarter. Geode Capital Management LLC now owns 220,047 shares of the company’s stock valued at $220,000 after purchasing an additional 52,875 shares during the period. Finally, Armistice Capital LLC bought a new position in shares of Citius Oncology in the 3rd quarter worth $15,582,000. 70.52% of the stock is owned by institutional investors and hedge funds.

Citius Oncology Company Profile

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.